Clinical trials: Apixaban
Healthy Participants
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants.
- Trial name
- NCT07312851
- Testing
- Andexanet alfa, Rivaroxaban, Apixaban
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Apixaban
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03448783
- Testing
- Apixaban
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Thrombosis, Injury Leg
Thromboprophylaxis in Lower Limb Immobilisation
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
- Trial name
- TiLLI (NCT06370273)
- Testing
- Rivaroxaban, Apixaban, Enoxaparin Injectable Solution
- Where
- 5 sites in United Kingdom
- Volunteers
- 10,044 people
- Sponsor
- Queen Mary University of London
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Bladder Cancer
Comparison of Apixaban Versus Enoxaparin
The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder.
- Trial name
- CARE (NCT06243510)
- Testing
- apixaban, enoxaparin
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Traumatic Intracranial Haemorrhage
Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage
Older people falling from a standing height is the most common cause of hospital admission for head injury. Up to 1 in 3 patients admitted are taking a tablet medication which thins the blood, known as an oral anticoagulant.
- Trial name
- RESTARTtlCrH (NCT06322953)
- Testing
- Direct-Acting Oral Anticoagulants (used as per local standard practice)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,084 people
- Sponsor
- Walton Centre NHS Foundation Trust
Aortic Stenosis
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis.
- Trial name
- ACASA-TAVI (NCT05035277)
- Testing
- Acetylsalicylic acid, Apixaban, Rivaroxaban
- Where
- 3 sites in Norway
- Volunteers
- 360 people
- Sponsor
- Oslo University Hospital
Stroke, Ischemic Stroke
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay.
- Conditions
- Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation
- Trial name
- SPICAF (NCT06486792)
- Testing
- Apixaban, Aspirin
- Where
- France
- Volunteers
- 1,148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism, Varicose Veins
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin.
- Trial name
- THRIVE (NCT05735639)
- Testing
- Dalteparin Sodium, Tinzaparin Sodium, Enoxaparin Sodium
- Where
- United Kingdom
- Volunteers
- 3,175 people
- Sponsor
- Imperial College London
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Intracerebral Hemorrhage, Atrial Fibrillation
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).
- Trial name
- ASPIRE (NCT03907046)
- Testing
- Apixaban, Aspirin
- Where
- 187 sites in United States
- Volunteers
- 700 people
- Sponsor
- Yale University
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation.
- Conditions
- Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Hemorrhage
- Trial name
- CLOT-LESS (NCT07575867)
- Testing
- Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC
- Where
- Russia
- Volunteers
- 464 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis
Apixaban in Thrombocytopenia
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
- Trial name
- NCT06886516
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rushad Patell
Cirrhosis, Esophageal and Gastric Varices
Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing…
- Conditions
- Cirrhosis, Esophageal and Gastric Varices, Ascites, Hepatic Encephalopathy
- Trial name
- APIXABAN-PK (NCT07521332)
- Testing
- Apixaban, Carvedilol
- Where
- Pakistan
- Volunteers
- 220 people
- Sponsor
- Asian Institute Of Medical Sciences
Intracerebral Hemorrhage, Atrial Fibrillation
Avoiding Anticoagulation After IntraCerebral Haemorrhage
Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF).
- Conditions
- Intracerebral Hemorrhage, Atrial Fibrillation, Microhaemorrhage
- Trial name
- A3ICH (NCT03243175)
- Testing
- Apixaban 5 MG, left atrial appendage closure
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Lille
Cirrhosis, Splenectomy
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461532
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Splenectomy
Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy.
- Conditions
- Cirrhosis, Splenectomy, Portal Vein Thrombosis, Hypertension, Portal
- Trial name
- NCT07461545
- Testing
- Apixaban 2.5 MG
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Northern Jiangsu People's Hospital